Market revenue in 2020 | USD 709.7 million |
Market revenue in 2027 | USD 1,805.9 million |
Growth rate | 14.3% (CAGR from 2020 to 2027) |
Largest segment | Idarucizumab |
Fastest growing segment | Andexanet Alfa |
Historical data covered | 2016 - 2019 |
Base year for estimation | 2020 |
Forecast period covered | 2021 - 2027 |
Quantitative units | Revenue in USD million |
Market segmentation | Prothrombin Complex Concentrates, Phytonadione (Vitamin K), Andexanet Alfa, Idarucizumab, Protamine |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anticoagulant reversal drugs market will help companies and investors design strategic landscapes.
idarucizumab was the largest segment with a revenue share of 35.92% in 2020. Horizon Databook has segmented the Global anticoagulant reversal drugs market based on prothrombin complex concentrates, phytonadione (vitamin k), andexanet alfa, idarucizumab, protamine covering the revenue growth of each sub-segment from 2016 to 2027.
Horizon Databook provides a detailed overview of global-level data and insights on the Global anticoagulant reversal drugs market, including forecasts for subscribers. This global databook contains high-level insights into Global anticoagulant reversal drugs market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account